NCT03965767

Brief Summary

Functional Endoscopic Sinus surgery (FESS) is a surgery done for chronic rhinosinusitis after failure of medical treatment. Intraoperative bleeding poses a challenge to both the surgeon and anaesthetist. Although blood loss is not massive during FESS, bleeding may obscure the surgical field prolonging the time of surgery or even leading to incompletion of the surgery. Different methods have been used to improve the surgical field but none without side effects. The use of diathermy carries the risk of local tissue damage with the risk of subsequent bleeding. Local vasoconstrictors carry the risk of systemic absorption. Induced hypotension may not be suitable for all patients; besides, this may necessitates the use of more anaestheic drugs with their associated side effects. In addition, none of theses methods have provided ideal surgical field for the surgeon.1-3 Tranexamic acid, an antifibrinolytic agent, has been used to decrease surgical field bleeding in different surgeries showing effectiveness in its topical, oral and intravenous use.4-6 The aim of this study is to evaluate the effectiveness of local, intravenous and combined use of tranexamic acid in improving the surgical field quality during functional endoscopic sinus surgery.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
120

participants targeted

Target at P25-P50 for phase_3

Timeline
Completed

Started Apr 2019

Shorter than P25 for phase_3

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 25, 2019

Completed
29 days until next milestone

First Submitted

Initial submission to the registry

May 24, 2019

Completed
5 days until next milestone

First Posted

Study publicly available on registry

May 29, 2019

Completed
3 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 25, 2019

Completed
7 days until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2019

Completed
Last Updated

May 29, 2019

Status Verified

May 1, 2019

Enrollment Period

4 months

First QC Date

May 24, 2019

Last Update Submit

May 24, 2019

Conditions

Keywords

endoscopic sinus surgery- tranexamic acid

Outcome Measures

Primary Outcomes (1)

  • bleeding during surgery

    surgeon satisfaction

    time of surgery

Study Arms (4)

control

PLACEBO COMPARATOR
Drug: Tranexamic Acid

local group

ACTIVE COMPARATOR
Drug: Tranexamic Acid

systemic group

ACTIVE COMPARATOR
Drug: Tranexamic Acid

combined local and systemic

ACTIVE COMPARATOR
Drug: Tranexamic Acid

Interventions

comparison of effect of tranexamic acid on control of bleeding when used locally in the nose or systemic use

combined local and systemiccontrollocal groupsystemic group

Eligibility Criteria

Age18 Years - 50 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • patients underwent endoscopic sinus surgery

You may not qualify if:

  • patients with uncontrolled hypertension or coronary artery disease, anaemia, end stage renal failure, liver cirrhosis, patients with coagulopathy or receiving drugs influencing blood coagulation, cerebrovascular thrombosis or history of thrombotic events, pregnancy, known sensitivity to any of the study drug and patients' refusal to participate in the study.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Faculty of Medicine Ain Shams University

Cairo, Egypt

RECRUITING

MeSH Terms

Conditions

Nasal Polyps

Interventions

Tranexamic Acid

Condition Hierarchy (Ancestors)

Nose DiseasesRespiratory Tract DiseasesOtorhinolaryngologic DiseasesPolypsPathological Conditions, AnatomicalPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Cyclohexanecarboxylic AcidsAcids, CarbocyclicCarboxylic AcidsOrganic Chemicals

Central Study Contacts

Research ethics comittee

CONTACT

Study Design

Study Type
interventional
Phase
phase 3
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Ain Shams University

Study Record Dates

First Submitted

May 24, 2019

First Posted

May 29, 2019

Study Start

April 25, 2019

Primary Completion

August 25, 2019

Study Completion

September 1, 2019

Last Updated

May 29, 2019

Record last verified: 2019-05

Locations